ABIVAX Signs Agreement with the Finlay Institute to Commercialise Meningococcal and Typhoid Vaccines in Asia and Latin America

November 12, 2014 ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today announced that it has signed an agreement with The Finlay Institute, Havana, Cuba, that will allow it to commercialise vaccines against typhoid, meningococcus, and leptospirosis, in Asian and Latin American markets. Under the terms of the agreement, ABIVAX will gain exclusive …

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% reduction in hospitalisations caused by …

Sanofi Pasteur’s Dengue vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America

Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes – Additional observation of the results shows a significant reduction of the risk of hospitalization by 80.3 percent confirming the potential public health impact of the vaccine Initial safety data are consistent with the …

Social investment for the development of sustainable public health solutions in Latin America

Carlos Slim Health Institute is a non-profit organization created in 2007 to develop and fund programs aimed at helping to solve health problem in Latin America. Dr Miguel Betancourt-Cravioto, Director, Global Solutions at the institute joined us at the World Vaccine Congress Washington 2012 to discuss their work and their success in putting into action health programs in Latin America. …